top of page
Saline: (734) 429-9053
Dexter: (734) 426-6210

Compounding for Diabetes + Weight Management

Jensen’s Community Pharmacy’s compounding lab has a created a GLP-1 suspension for diabetes and weight management. Our compounded Semaglutide for sublingual (under the tongue) administration is an excellent option for patients looking for an effective alternative to injectable GLP-1s.
apple and measuring tape

What is Semaglutide?

Semaglutide belongs to a class of medications known as glucagon-like peptide-1 (GLP-1) receptor agonists. They mimic the GLP-1 hormone that is released in the gut as a response to eating.

GLP-1 medications have taken the world by storm for their effectiveness in lowering blood sugar and reducing weight. Semaglutide (the primary ingredient in WEGOVY® and OZEMPIC®) and Tirzepatide (the primary ingredient in MOUNJARO® and ZEPBOUND™) are the most frequently prescribed.
carefree woman

How does it work?

GLP-1 send signals to the brain to regulate appetite and food intake. In certain amounts, Semaglutide works to suppress appetite, lower blood sugar, control blood sugar spikes, and reduce cravings. When used in conjunction with diet and exercise, it can help patients lose weight.
mortar and pestle

Why choose compounded Semaglutide?



Avoid Injections

Supply chain shortages of traditional GLP-1s make it difficult to obtain easily and regularly.
Many insurances do not cover traditional GLP-1s and the out-of-pocket cost is not affordable for most people.
The primary route of administration for traditional GLP-1s is subcutaneous injection which is not preferred by many patients, especially those with an aversion to needles.

Our compounded Semaglutide is more affordable, more consistently available, and easier to administer than other options on the market.

Plus, our compounded product is made using FDA-approved sources for the active ingredient and a suspension vehicle researched and manufactured for these medications to be absorbed under the tongue.

RYBELSUS®, OZEMPIC® and WEGOVY® are all registered trademarks of Novo Nordisk A/S. MOUNJARO® and ZEPBOUND™ are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. No compounded medication is reviewed by FDA for safety or efficacy.

Ready to get started?

If you are interested in getting more information for this affordable, simple to administer option, please fill out the contact form below. Please note that this compounded medication requires a prescription from your provider. If you have any concerns about obtaining a prescription, just let us know!
bottom of page